Sign In
Buy EQ
$3.11
+0.320 (+11.47%)
At Close: Jun 03, 2026
Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology
09:00am, Monday, 13'th Nov 2023
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #lupus--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammat
Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
04:01pm, Wednesday, 08'th Nov 2023
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
08:00am, Monday, 06'th Nov 2023
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammato
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory diso
Equillium to Present at the JonesTrading 2023 Healthcare Summit
08:00am, Monday, 02'nd Oct 2023
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis
Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences
08:00am, Wednesday, 20'th Sep 2023
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis
Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference
08:00am, Wednesday, 30'th Aug 2023
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat
Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates
06:59pm, Wednesday, 09'th Aug 2023
Equillium, Inc. (EQ) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.41 per share a year ago.
Equillium Announces $7.5 Million Share Repurchase Program
04:00pm, Wednesday, 02'nd Aug 2023
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
07:02pm, Thursday, 11'th May 2023
Equillium, Inc. (EQ) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.45 per share a year ago.
Equillium to Present at Two Upcoming Investor Conferences
08:00am, Tuesday, 08'th Nov 2022
LA JOLLA, Calif.
Why Is Equillium (EQ) Stock Soaring 20% Today?
02:20pm, Tuesday, 27'th Sep 2022
Clinical-stage biotechnology firm Equillium (NASDAQ: EQ ), which focuses on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, released encouraging clinical data rega
Equillium's stock is up 12% after sharing early data about its investigational lupus treatment
08:15am, Tuesday, 27'th Sep 2022
Shares of Equillium Inc. EQ, -3.98% gained 12.9% in premarket trading on Tuesday after the company shared a batch of interim data from an early stage trial evaluating its experimental treatment in 13
Equillium to Present at Two Upcoming Investor Conferences
08:00am, Wednesday, 31'st Aug 2022
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammato
Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Equillium, Inc. (EQ)
02:00pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
Equillium, Inc. (EQ) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revi
